VMD Medicines Update - August 2023 | British Equine Veterinary Association
  1. Resources
  2. Education
  3. Career support
  4. Get involved
  5. About us
BEVA Logo
  1. Resources
  2. Education
  3. Career support
  4. Get involved
  5. About us

VMD Medicines Update - August 2023

News Medicines
05 Oct 2023 BEVA

This medicines update is provided by the Veterinary Medicines Directorate (VMD) and lists new active substance, new marketing authorisations and changes to authorisations most relevant to vets.

New marketing authorisations

Table 1 shows the new marketing authorisations for August 2023

Novel active substances

Senvelgo 15 mg/ml Oral Solution for Cats is the first product authorised containing Velagliflozin, a sodium-glucose co-trans

porter 2 (SGLT-2) inhibitor, indicated for the treatment of diabetes mellitus in cats. 

TABLE 1: New marketing authorisations in August 2023

New Marketing Authorisations

Product name and target species

Active substance

Authorisation Holder, territory, and distribution category

Therapeutic group

 

Food Animals

Catophos 100 mg/ml + 0.05 mg/ml Solution for Injection for Horses, Cattle, Dogs and Cats

Butafosfan, Cyanocobalamin

CP Pharma Handelsgesellschaft mbH

NI

POM-V

Vitamin; Mineral

Presedine 10 mg/ml Solution for Injection for Horses

Detomidine hydrochloride

Alfasan Nederland B.V.

GB

POM-V

Neurological Agent sedative

Presedine 10 mg/ml Solution for Injection for Horses and Cattle

Detomidine hydrochloride

Alfasan Nederland B.V.

NI

POM-V

Neurological Agent sedative

 

See the VMD’s Product Information Database for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics sections have been revised/changed.

All entries can be found on the VMD’s Product Information Database.

Changes to the SPC, labels and leaflets may change how the medicines should be used. There may be a delay between these changes being authorised to implementation on product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Food producing animals

Molemec Plus Paste for Horses 15.5 mg/g / 77.5 mg/g Oral Paste              

Boehringer Ingelheim Animal Health UK Ltd          GB          POM-VPS

Section 4.6: Digestive discomfort (colic, loose stool) has been observed in very rare cases based on post-marketing surveillance data.          

For more information, contact the VMD at postmaster@vmd.gov.uk